{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:45:03Z","timestamp":1773085503398,"version":"3.50.1"},"reference-count":43,"publisher":"European Respiratory Society (ERS)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2002,8,27]]},"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:p>Based on recent guidelines for the management of community-acquired pneumonia, this study was designed to evaluate the effectiveness of a new fluoroquinolone compared with standard antimicrobial regimens, in conditions relating as closely as possible to the real world setting.<\/jats:p><jats:p>In this study, 564 patients were randomised to either oral moxifloxacin (400\u2005mg<jats:italic>o.d<\/jats:italic>.) or to standard oral therapy (amoxicillin 1\u2005g<jats:italic>t.i.d.<\/jats:italic>or clarithromycin 500\u2005mg<jats:italic>b.i.d.<\/jats:italic>alone or in combination) for up to 14 days using a double-blind procedure. The choice between the three standard regimens was made by the clinician prior to randomisation. Clinical response, quality of life, symptoms, healthcare resources and safety were assessed.<\/jats:p><jats:p>In the per-protocol population, clinical success was reported for 201 of 215 (93.5%) and 217 of 231 (93.9%) in the moxifloxacin and standard groups, respectively, at 7\u201310 days post-therapy. At 28\u201335 days follow-up, continued clinical cure was observed in 183 of 192 (95.3%) moxifloxacin and 207 of 221 (93.7%) standard groups. Drug-related adverse events were reported in 55 of 274 (20%) moxifloxacin and 86 of 279 (31%) standard patients with diarrhoea &gt;5%.<\/jats:p><jats:p>Oral moxifloxacin monotherapy was as effective as, and better tolerated than, optimal antibiotic strategy represented either by mono- or combination therapy (amoxicillin and\/or clarithromycin) in community-acquired pneumonia management.<\/jats:p>","DOI":"10.1183\/09031936.03.00045202","type":"journal-article","created":{"date-parts":[[2003,1,10]],"date-time":"2003-01-10T23:46:55Z","timestamp":1042242415000},"page":"135-143","source":"Crossref","is-referenced-by-count":69,"title":["Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia"],"prefix":"10.1183","volume":"21","author":[{"given":"A.","family":"Torres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-F.","family":"Muir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Corris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Duprat-Lomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P-P.","family":"Sagnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"H\u00f6ffken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2003,1,1]]},"reference":[{"key":"2024101810005682000_21.1.135.1","unstructured":"Intercontinental Marketing Society Health StatisticsMadrid, Spain, 2001."},{"key":"2024101810005682000_21.1.135.2","first-page":"556","volume":"46","year":"1997","journal-title":"Morb Mortal Wkly Rpt"},{"key":"2024101810005682000_21.1.135.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530270029027"},{"key":"2024101810005682000_21.1.135.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530260048030"},{"key":"2024101810005682000_21.1.135.5","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440360129015"},{"key":"2024101810005682000_21.1.135.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80144-6"},{"key":"2024101810005682000_21.1.135.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701233360402"},{"key":"2024101810005682000_21.1.135.8","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440220040006"},{"key":"2024101810005682000_21.1.135.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00500-3"},{"key":"2024101810005682000_21.1.135.10","doi-asserted-by":"publisher","DOI":"10.1086\/313954"},{"key":"2024101810005682000_21.1.135.11","doi-asserted-by":"publisher","DOI":"10.1086\/313959"},{"key":"2024101810005682000_21.1.135.12","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.11040986"},{"key":"2024101810005682000_21.1.135.13","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.10.1399"},{"key":"2024101810005682000_21.1.135.14","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.163.7.at1010"},{"key":"2024101810005682000_21.1.135.15","first-page":"65","volume":"4","year":"2001","journal-title":"Value Health"},{"key":"2024101810005682000_21.1.135.16","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"2024101810005682000_21.1.135.17","unstructured":"Ware JE.. SF-36 Health Survey, Manuel Interpretation GuideBoston, The Medical Outcomes Trust, 1993."},{"key":"2024101810005682000_21.1.135.18","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199915050-00001"},{"key":"2024101810005682000_21.1.135.19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/bmj.319.7211.652","volume":"319","year":"1999","journal-title":"BMJ"},{"key":"2024101810005682000_21.1.135.20","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)00141-C"},{"key":"2024101810005682000_21.1.135.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00151-6"},{"key":"2024101810005682000_21.1.135.22","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(95)00530-7"},{"key":"2024101810005682000_21.1.135.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7127.285"},{"key":"2024101810005682000_21.1.135.24","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(67)90041-0"},{"key":"2024101810005682000_21.1.135.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)03053-5"},{"key":"2024101810005682000_21.1.135.26","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(94)90024-8"},{"key":"2024101810005682000_21.1.135.27","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(94)90022-1"},{"key":"2024101810005682000_21.1.135.28","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.1.185"},{"key":"2024101810005682000_21.1.135.29","doi-asserted-by":"publisher","DOI":"10.1086\/516366"},{"key":"2024101810005682000_21.1.135.30","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.suppl_1.73"},{"key":"2024101810005682000_21.1.135.31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s100960050106","volume":"17","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024101810005682000_21.1.135.32","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1128\/AAC.41.9.1965","volume":"41","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2024101810005682000_21.1.135.33","doi-asserted-by":"publisher","DOI":"10.1080\/00365549850160710"},{"key":"2024101810005682000_21.1.135.34","unstructured":"Adams M, Sullivan J, Henry D, et al. Comparison of grepafloxacin with cefaclor in the treatment of community-acquired pneumonia In:. Program and Abstracts of the 37th International Conference on Antimicrobial Agents and ChemotherapyToronto, American Society for Microbiology, 1997; p. 377."},{"key":"2024101810005682000_21.1.135.35","unstructured":"Niederman M, Traub S, Ellison WT, Hopkins DW, the TROVAN Pneumonia Study Group. A double-blind, randomized, multicenter, global study in trovafloxacin with ceftriaxone plus erythromycin [abstract LM-72] In:. Program and Abstracts of the 37th International Conference on Antimicrobial Agents and ChemotherapyToronto, American Society for Microbiology, 1997; pp. 377\u2013378."},{"key":"2024101810005682000_21.1.135.36","first-page":"748","volume":"16","year":"1999","journal-title":"Infect Med"},{"key":"2024101810005682000_21.1.135.37","unstructured":"Moola S, Hagberg L, Churchyard A, Sedani S, Staley H, the RAXAR CAP Study Group. Comparison of grepafloxacin with clarithromycin in the treatment of community-acquired pneumonia (CAP) In:. Program and Abstracts of the 38th International Conference on Antimicrobial Agents and ChemotherapySan Diego, American Society for Microbiology, 1998; p582."},{"key":"2024101810005682000_21.1.135.38","unstructured":"Patel T, Desai R, Duff J, Johnson ME, Breisch SA, Maroli AN.. Comparison of grepafloxacin (GFX) with clarithromycin (CLA) in the treatment of community-acquired pneumonia (CAP) In:. Program and Abstracts of the 37th International Conference on Antimicrobial Agents and ChemotherapyToronto, American Society for Microbiology, 1997; p. 378."},{"key":"2024101810005682000_21.1.135.39","unstructured":"Sullivan J, Gezon J, Williams-Hopkins D, the TROVAN Pneumonia Study Group. A double-blind, randomized multicenter study in ambulatory community-acquired pneumonia (CAP) comparing trovafloxacin with clarithromycin In:. Program and Abstracts of the 37th International Conference on Antimicrobial Agents and ChemotherapyToronto, American Society for Microbiology, 1997; p. 378."},{"key":"2024101810005682000_21.1.135.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88271-5"},{"key":"2024101810005682000_21.1.135.41","doi-asserted-by":"publisher","DOI":"10.1378\/chest.110.6.1499"},{"key":"2024101810005682000_21.1.135.42","doi-asserted-by":"publisher","DOI":"10.1086\/319615"},{"key":"2024101810005682000_21.1.135.43","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.3.358.34205"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09031936.03.00045202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:16:25Z","timestamp":1740377785000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09031936.03.00045202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2003,1,1]]},"published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1183\/09031936.03.00045202"],"URL":"https:\/\/doi.org\/10.1183\/09031936.03.00045202","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}